NCT02851992

Brief Summary

This is a multicenter, non-controlled, prospective study. 303 subjects (GTS standard and lateralized) have been recruited. Study will be conducted in centers across Europe.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
303

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Sep 2012

Longer than P75 for not_applicable

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2012

Completed
3.9 years until next milestone

First Submitted

Initial submission to the registry

July 25, 2016

Completed
8 days until next milestone

First Posted

Study publicly available on registry

August 2, 2016

Completed
3.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2020

Completed
3.6 years until next milestone

Results Posted

Study results publicly available

December 1, 2023

Completed
1.4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2025

Completed
Last Updated

August 10, 2026

Status Verified

July 1, 2026

Enrollment Period

7.7 years

First QC Date

July 25, 2016

Results QC Date

July 7, 2023

Last Update Submit

July 16, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Mean Harris Hip Score

    Harris Hip Score (HHS) tests will be carried out pre-operatively and at each follow-up period. The HHS covers four domains: pain (one item, 0-44 points), function and functional activities (seven items, 0-47 points), absence of deformity (one item, 0-4 points) and range of motion (one item, 0-5 points). To obtain a final score, the points are summed. The minimum and maximum values of the scale are 0-100, with a higher score indicating a better outcome. The outcome score can be categorized as Excellent: 90-100; Good: 80-90; Fair: 70-80; Poor: \< 70.

    Pre-operatively, 3 months and 1, 2, 3, 5, 7, and 10 years post-operatively.

Secondary Outcomes (4)

  • Stability, Incidence of Radiolucencies Around the Prosthesis and Bone Remodeling

    10 years post-surgery.

  • Patient Satisfaction

    Pre-operatively, 3 months and 1, 2, 3, 5, 7, and 10 years post-surgery

  • Adverse Events/Complications

    From surgery through the 10-year post-operative follow-up period.

  • Revision-Free Survivorship Through 10 Years

    From implantation through 10 years post-operatively

Study Arms (1)

GTS cementless stem

OTHER

Total Hip arthroplasty with GTS cementless stem (standard and lateralized) with different cup and bearing options (metal-on-polyethylene or ceramic-on-polyethylene)

Device: GTS cementless stem

Interventions

Total Hip Arthroplasty

GTS cementless stem

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Primary osteoarthritis or secondary coxarthritis
  • Inflammation of the hip: rheumatoid arthritis, etc.
  • Femoral neck fracture
  • Avascular necroses of the femoral head
  • Sequelae from previous operations on the hip, osteotomies, etc.
  • Congenital hip dysplasia
  • years of age or older
  • Subjects willing to return for follow-up evaluations
  • Subjects who read, understood study information and provided an informed written consent (specific local regulatory requirements)

You may not qualify if:

  • Absolute contraindications include:
  • Local or systemic infections.
  • Severe muscular, neurological or vascular deficiencies of the extremity involved
  • Bone destruction or poor bone quality that is likely to affect implant stability(Paget's disease, osteoporosis, etc.)
  • Concomitant disease likely to affect implant function
  • Allergy to any of the components of the implant
  • Patients weighing more than 110 kg
  • Subjects unable to co-operate with and complete the study
  • Dementia and/or inability to understand and follow instructions
  • Neurological conditions affecting movement
  • Patient over 18 under law supervision

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Osteoarthritis, Hip

Condition Hierarchy (Ancestors)

OsteoarthritisArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Limitations and Caveats

The study was terminated prematurely, resulting in limited participant follow-up beyond 7 years and reduced long-term data availability.

Results Point of Contact

Title
Emilie Rohmer, Clinical Operations Assoc Director
Organization
Zimmer Biomet

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 25, 2016

First Posted

August 2, 2016

Study Start

September 1, 2012

Primary Completion

May 1, 2020

Study Completion

May 1, 2025

Last Updated

August 10, 2026

Results First Posted

December 1, 2023

Record last verified: 2026-07

Data Sharing

IPD Sharing
Will not share